These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26165687)

  • 21. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
    Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
    Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
    Zhou W; Jirström K; Amini RM; Fjällskog ML; Sollie T; Lindman H; Sørlie T; Blomqvist C; Wärnberg F
    BMC Cancer; 2013 Oct; 13():512. PubMed ID: 24171825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
    Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
    Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of androgen receptor in breast cancer and its significance as a prognostic factor.
    Yu Q; Niu Y; Liu N; Zhang JZ; Liu TJ; Zhang RJ; Wang SL; Ding XM; Xiao XQ
    Ann Oncol; 2011 Jun; 22(6):1288-1294. PubMed ID: 21109569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
    Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
    Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors.
    Selim AG; El-Ayat G; Wells CA
    J Clin Pathol; 2002 Jan; 55(1):14-6. PubMed ID: 11825917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.
    Clark SE; Warwick J; Carpenter R; Bowen RL; Duffy SW; Jones JL
    Br J Cancer; 2011 Jan; 104(1):120-7. PubMed ID: 21139586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model of immunohistochemical differences between invasive breast cancers and DCIS lesions tested on a consecutive case series of 1248 patients.
    Kurbel S; Marjanović K; Dmitrović B
    Theor Biol Med Model; 2014 Jun; 11():29. PubMed ID: 24917206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient.
    Kim C; Lee J; Lee W; Kim A
    Int J Clin Exp Pathol; 2015; 8(11):15184-90. PubMed ID: 26823864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
    Takagi K; Miki Y; Nakamura Y; Hirakawa H; Kakugawa Y; Amano G; Watanabe M; Ishida T; Sasano H; Suzuki T
    Histol Histopathol; 2015 Oct; 30(10):1223-32. PubMed ID: 25873048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
    Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
    Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
    [No Abstract]   [Full Text] [Related]  

  • 40. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
    Tran DD; Lawson JS
    Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.